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Abstract
Although liposomes have proven useful for the delivery of drugs and gene therapy vectors, their potencies are often
compromised by poor unloading following uptake into their target cells. We have consequently explored the properties of a
novel 29-residue amphipathic peptide that was designed by arrangement of hydrophobic and hydrophilic residues to disrupt
liposomes at lower peptide concentrations than previously tested peptides. The peptide was indeed found to promote pH-
dependent liposome unloading with improved efficiency. A peptide of the same sequence, but half the length, however,
promoted pH-dependent permeabilization only at much higher concentrations. Further characterization of the longer
peptide revealed that release of liposome contents (i) occurred at a pH of V6, (ii) became less efficient as the size of the
encapsulated cargo increased, and (iii) was moderately suppressed in cholesterol-containing liposomes. Use of this peptide to
enhance the cytotoxicity of cytosine arabinoside encapsulated in folate-targeted liposomes demonstrated an increase in drug
potency ofV30-fold. Gene expression by a serum-stable folate-targeted liposomal vector was also measurably enhanced by
inclusion of the peptide. We conclude that intracellular unloading of liposomal contents can be significantly improved by co-
encapsulation of an optimally designed, pH-sensitive peptide. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes have shown considerable promise as
vehicles for the delivery of small molecular mass
drugs to tumors [1^3]. Indeed, the potency and nor-
mal tissue toxicity of doxorubicin has been signi¢-
cantly improved by encapsulating the drug into
long circulating liposomes [4,5]. Unfortunately, the
e⁄cacy of liposomal drug delivery has not achieved
its full potential, in part because of the slow escape
of the encapsulated drugs following uptake of the
liposomes by target cells [6^8]. However, target cell
endocytosis generally tra⁄cs the liposomes into en-
dosomes [9,10] and the low pHs characteristic of
these compartments may be exploited for liposome
unloading. Such e¡orts to accelerate drug release
have largely focused on the development of pH-sen-
sitive lipids that are rapidly hydrolyzed or protonat-
ed following endocytosis into an acidic intracellular
compartment [11^13]. Alternatively, pH-dependent
peptides that mimic viral fusion peptides have also
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been designed to enable release of liposome contents
at acidic pHs [14^16].
The mechanism by which fusogenic peptides medi-
ate liposome unloading probably involves a change
in peptide conformation following exposure to acidic
pHs [17]. Thus, at neutral pH, the peptides are
largely seen in random coil conformations, but at
pH values near 5, the peptides convert predomi-
nantly to amphipathic helices [18]. As a consequence
of this conformational transition, these peptides in-
sert into the liposome bilayer and self-associate,
causing leakage of encapsulated contents [18]. Be-
cause the pH dependence of the conformational tran-
sition can be highly cooperative, amphipathic pep-
tides have the potential of displaying no membrane
activity during liposome circulation in the blood (pH
7.4), but inducing quantitative permeabilization fol-
lowing entry of the liposome into the cell (pH 4.5^
6.5).
The GALA peptide was the ¢rst peptide to be
speci¢cally designed for pH-dependent liposome un-
loading [19], and various related peptides have since
been synthesized and characterized for their pH-de-
pendent pore-forming properties [20,21]. We have
also synthesized a 30-amino-acid GALA-type pep-
tide, called EALA, and demonstrated its ability to
promote the speci¢c unloading of liposomes in endo-
somes of the folate receptor endocytic pathway [22].
With this peptide, liposomes could be readily con-
structed that were stable during storage in neutral
bu¡er for longer than 1 month, but still unloaded
their contents upon endocytosis by target cells.
Although EALA allowed for good liposome stabil-
ity and pH-dependent unloading properties, we still
felt motivated to improve its potency in order to
minimize the number of peptides required to facili-
tate liposome permeabilization. For this purpose, we
explored the hypothesis that the number of peptides
per liposome required to enable cargo unloading
might depend on the fraction of the peptide’s surface
area occupied by hydrophilic groups (see Section 3).
Based on this concept, we have designed a peptide
with superior pH-dependent membrane-permeabiliz-
ing properties. In this paper, we characterize the nov-
el peptide’s liposome-destabilizing capacity under a
variety of conditions and examine its ability to en-
hance the potency of encapsulated cytotoxic drugs
and gene therapy vectors.
2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (98% purity), cholesterol,
n-glutaryl-phosphatidylethanolamine (glutaryl-PE),
and dioleyltrimethylammonium-propane (DOTAP)
were all purchased from Avanti Polar Lipids
(Alabaster, AL). Polyethyleneglycol-bis-amine
(H2N-PEG-NH2) Mr 3400 was purchased from
Shearwater Polymers (Huntsville, AL). Texas Red
dextrans of MrV10 000 and V40 000 were from
Molecular Probes (Eugene, OR). [3H]Thymidine
was purchased from American Radiolabeled Chem-
icals (St. Louis, MO). KB cells were a generous do-
nation from the Purdue University Cancer Center,
and all cell culture media and reagents were obtained
from Gibco BRL (Gaithersburg, MD). Cytosine L-D-
arabinofuranoside (ara-C) and all other reagents
were from Sigma Chemical Co. (St. Louis, MO).
2.2. Peptide synthesis
The 29-amino-acid peptide, H2N-(AALEALAEA-
LEALAEALEALAEAAAAGGC)-CO2H, and the
previously characterized 30-amino-acid EALA pep-
tide, H2N-(AALAEALAEALAEALAEALAEALA-
AAAGGC)-CO2H, were synthesized by the Purdue
University Peptide Synthesis Facility using solid
phase methodology based on an Fmoc strategy.
The 15-amino-acid peptide H2N-(ALEALAEALEA-
LAEA)-CONH2 was synthesized by Peptidogenic
(Livermore, CA). All peptides were puri¢ed to great-
er than 95% homogeneity, as determined by analyt-
ical high-performance liquid chromatography, and
characterized by fast atom bombardment mass spec-
trometry.
2.3. Synthesis of folate-PEG-PE conjugate
Folate-PEG-PE was synthesized as described pre-
viously [23], with the following modi¢cations.
(1) After coupling 1 equivalent folic acid to H2N-
PEG-NH2 with dicyclohexylcarbodiimide, the prod-
uct was puri¢ed on a G-15 size exclusion column in
ddH2O. (2) The puri¢ed folate-PEG-NH2 was con-
jugated directly to n-glutaryl-PE via carbodiimide
coupling. (3) Following completion of the conjuga-
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tion reaction, the chloroform was evaporated and the
resulting solid was dissolved in ddH2O for puri¢ca-
tion by passage through a CL4B column. The early
micellar fraction was collected and lyophilized to
yield the ¢nal product, folate-PEG-PE.
2.4. Preparation of small unilammelar vesicles
All liposomes were comprised of 100% egg phos-
phatidylcholine with the exception of propidium io-
dide encapsulating liposomes, which contained 0, 20
or 40 mol% cholesterol, and ara-C liposomes which
contained 0.5 mol% folate-PEG-PE for tumor target-
ing. All lipids were ¢rst dissolved in chloroform and
then dried to a thin ¢lm by rotary evaporation. For
the unloading studies, thin ¢lms were rehydrated by
addition of phosphate-bu¡ered saline (PBS) (pH
7.4), containing propidium iodide (2 mg/ml) or Texas
Red dextran of Mr 10 000 or 40 000 Da (5 mg/ml).
Propidium iodide (PI) and dextran-containing lipo-
somes did not contain peptide, rather peptides were
added externally to pre-formed liposomes in solu-
tion. In order to test the ability of the 29-residue
peptide to enhance delivery of a cytotoxic drug, lipo-
somes containing ara-C were prepared with co-en-
capsulated peptide. Folate-targeted ara-C liposomes
were rehydrated in PBS containing ara-C (10 mg/ml)
with or without the 29-amino-acid peptide (2 mg/ml).
Rehydration was accomplished by vigorous vortex-
ing followed by ¢ve cycles of freezing and thawing.
All liposome preparations were then sized by extru-
sion ten times through a 100-nm pore size polycar-
bonate membrane using a high-pressure extruder
(Lipex Biomembranes, Vancouver, BC, Canada). Fi-
nally, liposomes were separated from unencapsulated
material by passage through a size exclusion column
equilibrated in PBS. CL4B size exclusion resin was
used in all cases except for Texas Red dextran 40 000
Mr containing liposomes, which were puri¢ed using
CL6B resin. Final encapsulation e⁄ciency of the 29-
residue peptide, as determined by amino acid analy-
sis, was approximately 0.1%, yielding an intraliposo-
mal peptide concentration of V10 WM.
Liposomal ara-C concentration was determined by
measuring the drug’s absorbance at 272 nm on a
Shimadzu Biospec-1601 UV-Visible spectrophotome-
ter. Empty liposomes were used as a background for
this determination. All liposomes were stored at 4‡C
and used within 1 week of preparation.
2.5. PI release assay
Although a method for quantitating the unloading
of liposomal contents from endosomal compartments
of cultured cells has already been reported [22], a
related, but simpler approach was developed for
the rapid screening of various peptide formulations
for their abilities to permeabilize liposomes. PI is a
pH-insensitive membrane impermeable dye that £uo-
resces only upon binding polynucleic acids [22]. Its
£uorescence is consequently negligible when en-
trapped in the aqueous lumen of liposomes, but in-
tense when released into a solution containing calf
thymus DNA. For analysis of peptide-induced PI
release, PI-containing liposomes in PBS were added
to one of the following bu¡ers: 100 mM citrate, pH
4.0 or 4.5; 100 mM citrate/phosphate, pH 5.0 or 5.5;
100 mM phosphate, pH 6.0, 6.5, or 7.0; or PBS, pH
7.4. Small volumes of peptide stock solutions in PBS
(pH 8.0) were then added to the liposome suspen-
sions to achieve the desired lipid to peptide molar
ratios, and suspensions were stirred at room temper-
ature for various time periods. Calf thymus DNA
dissolved in PBS was then added to the liposome
suspensions (0.02 mg/ml ¢nal concentration), and
the £uorescence was measured (released propidium
iodide £uorescence) in an Aminco Bowman Series 2
luminescence spectrometer using 495-nm excitation
and 515-nm emission wavelengths. A sample contain-
ing liposomes plus DNA in the appropriate bu¡er,
but without the addition of peptide, was subtracted
from each test sample to account for the minimal
background £uorescence of PI that remained encap-
sulated (£uorescence of blank). Further, it was con-
¢rmed that the £uorescence of PI did not increase
when combined in solution with relevant concentra-
tions of the 29-residue peptide. To determine the
maximum PI release possible for each sample, 0.1%
of reduced Triton X-100 detergent was added to the
liposome suspension at the end of each experiment
and the £uorescence was again measured (maximum
possible £uorescence). Percent PI released was calcu-
lated as (released £uorescence3£uorescence of
blank)U100/(maximum possible £uorescence).
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2.6. Dextran release assay
Dextrans were chosen as macromolecular markers
for sizing peptide pores because they are membrane-
impermeable, water-soluble, and available in a range
of sizes. To quantitate the peptide-induced release of
10 000 and 40 000 Da dextrans from liposomes, dex-
tran-loaded liposomes in PBS were added to bu¡ers
at speci¢c pHs, peptide was then added, and samples
were stirred as described for the PI release assay.
Liposomes were then passed through a CL4B or
CL6B size exclusion column (equilibrated in PBS)
to separate released dextran from liposomal dextran.
Fractions were collected until all dextran had eluted
from the column, and reduced Triton X-100 deter-
gent (0.01% ¢nal concentration) was added to each
fraction to eliminate liposome-related quenching and
light-scattering e¡ects. The £uorescence of each frac-
tion was then determined by exciting at 595 nm,
while monitoring emission at 615 nm, and percent
dextran released was calculated at each pH as fol-
lows: (sum of £uorescence of non-liposome frac-
tions)U100/(sum of £uorescence of all fractions).
2.7. Cell culture
Folate receptor positive KB cells were cultured in
folate-de¢cient Minimal Essential Medium
(FDMEM) to allow for sustained and elevated ex-
pression of the folate receptor. Medium contained
10% heat-inactivated fetal calf serum (FCS), penicil-
lin (50 units/ml), streptomycin (50 Wg/ml), 2 mM L-
glutamine and non-essential amino acids at 37‡C in a
5% CO2 humidi¢ed atmosphere. For ara-C cytotox-
icity studies, cells were seeded 24 h prior to each
experiment in 24-well plates at approximately 25%
con£uence. In a typical liposomal vector transfection
experiment, cells were seeded 48 h before transfection
in 24-well plates at 15^20% con£uence.
2.8. [3H]Thymidine incorporation assay
Triplicate wells containing KB cells in FDMEM
were incubated for 4 h at 37‡C with folate-targeted
liposomes containing ara-C with or without co-en-
capsulated peptide. 1 mM folic acid was pre-added
to selected wells as a competitive ligand to demon-
strate that uptake of the liposomes was mediated
by the folate receptor. Following incubation, cells
were washed three times with PBS and incubated
an additional 24 h in FDMEM containing 1 WCi
[3H]thymidine per well [24]. After this second incu-
bation, cells were again washed three times in PBS
and dissolved in 0.2 M NaOH containing 1% Triton
X-100. Liquid scintillation counting was used to de-
termine the amount of radioactive thymidine incor-
porated by the cells in each well, and percent growth
inhibition was calculated relative to the maximum
thymidine incorporation by cells in untreated wells.
2.9. Plasmid preparation
Escherichia coli (XL1 blue) cells were transformed
with pGL3 vector containing the luciferase reporter
gene (Promega, Madison, WI) and selected in an
ampicillin rich growth medium at 37‡C overnight.
A single clone of transfected E. coli was further pro-
liferated in LB broth (containing 100 Wg ampicillin/
ml) at 37‡C with vigorous agitation and aeration for
18 h. E. coli cultures with OD600s 3.0 were harvest-
ed and pGL3 plasmid DNA was puri¢ed by alka-
line lysis and use of Biggest prep puri¢cation kit
(5 primeC3 prime Inc., Boulder, CO).
2.10. Preparation of cationic liposome/DNA
complexes
Liposomes for transfection studies were prepared
by drying a chloroform solution of DOTAP (1
Wmol), cholesterol (0.67 Wmol), and 0.5 mol% fo-
late-PEG-PE (targeted) or PEG-PE (non-targeted)
under vacuum to a thin ¢lm. The ¢lm was hydrated
by addition of 1.0 ml sterile 5% dextrose in 5 mM
HEPES (pH 8.0). Liposomes were prepared by ¢rst
vortexing the hydrated lipid for 1 min and then ro-
tating the sample in a water bath at 50‡C for 45 min
and then 35‡C for 10 min. The suspension was al-
lowed to stand at room temperature overnight and
then subjected to sonication in a bath sonicator to
obtain a clear emulsion [25]. Peptide and DNA were
dissolved in sterile 5% dextrose in 5 mM HEPES (pH
7.4) at peptide/DNA weight ratios ranging from 0.1^
1.6. Liposome/peptide/DNA complexes were induced
to self-assemble by vortexing equal volumes of the
DOTAP/cholesterol suspension and the peptide/
DNA mixture dissolved in sterile 5% dextrose in
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5 mM HEPES (pH 7.4) for 1 min, followed by in-
cubation at room temperature for 15 min.
2.11. Transfection of cells with DOTAP/cholesterol
liposomal vectors
Immediately prior to transfection, KB cells were
washed with 0.5 ml of FDMEM þ 10% FCS, and
then incubated for 4 h at 37‡C with DNA/liposome
complexes with or without peptide in 400 Wl
FDMEM þ 10% fetal calf serum (FCS). After 4 h
incubation, the medium containing any free DNA/
liposome complexes was removed and the cells were
returned to culture with 0.5 ml FDMEM+10% FCS.
Thirty-six hours after transfection, cells were ana-
lyzed for reporter gene expression using the Lucifer-
ase Assay system (Promega, Madison, WI). Measure-
ment of relative light units (RLU) of the luciferase
enzymatic product was performed on a Microtiter
Plate Luminometer (Dynex Technologies, Chantilly,
VA) and reported relative to the concentration of cell
lysate protein in each sample. Protein concentration
was determined using the BCA assay (Pierce Chem-
ical Co., Rockford, IL).
3. Results
3.1. Design of an optimal peptide sequence for
membrane permeabilization
Because the peptide variants examined in this
study were nearly 90% K-helical (determined by cir-
cular dichroism, data not shown), the peptide se-
quences were ¢t to an idealized helical wheel in an
e¡ort to predict their geometries of self assembly
within a phospholipid bilayer. When negatively
charged glutamic acid residues are distributed over
a large angle of an amphipathic peptide helix, multi-
ple copies of the peptide may have to associate with-
in a lipid bilayer to avoid energetically unfavorable
contacts between glutamic acid side chains and bi-
layer lipids (see Fig. 1A). Consequently, the resulting
peptide-lined pore is expected to be large. In con-
trast, when the hydrophilic glutamic acid residues
constitute a smaller angle of the peptide helix, mem-
brane pores could conceivably be assembled with
fewer peptide monomers, enabling permeabilization
at lower peptide concentrations (Fig. 1A). Assuming
an average radial rotation of V100‡/residue and a
helical diameter of V10 Aî , we determined that the
amino acid sequence requiring the fewest monomers
per aqueous pore was AALEALAEALEALAEA-
LEALAEAAAAGGC. As seen in the helical wheel
of Fig. 1B, this peptide localizes all hydrophilic res-
idues within a 90‡ angle on one side of the helix.
Consequently, a tetramer should hypothetically con-
stitute the preferred oligomer in the membrane (Fig.
1A). This 29-amino-acid peptide plus a truncated 15-
residue version of the same sequence were, therefore,
constructed and examined for their liposome perme-
abilization properties (Fig. 1B).
3.2. The novel 29-amino-acid peptide catalyzes rapid
pH dependent liposome permeabilization to both
propidium iodide and a 10 000 Da dextran
In order to determine whether the newly designed
29-residue peptide was membrane active, it was
added to preformed liposomes containing either a
low molecular mass solute (propidium iodide, PI)
or a 10 000 Da Texas Red-labeled dextran. After
acidi¢cation of the suspension to pH 4, release of
liposome contents was evaluated as a function of
time. As seen in Fig. 2, release of both PI and dex-
tran from the liposomes occurred rapidly, reaching a
maximum within V10 min of peptide addition.
However, whereas PI was able to fully escape the
liposome interior, the high molecular mass dextran
was not. Importantly, release kinetics were similar
for the 15-amino-acid peptide and the previously de-
scribed EALA peptide (data not shown). Because of
these similar kinetics, percent release was subse-
quently determined 10 min following peptide addi-
tion in all other studies. Importantly, no leakage of
liposome contents could be detected during similar
incubations at neutral pH, suggesting that the lipo-
somes might remain stable during circulation in the
blood.
3.3. The novel 29-amino-acid peptide is signi¢cantly
more potent than EALA
Our objective in designing a new peptide was to
identify a sequence that could promote liposome un-
loading at lower peptide concentrations than the pre-
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viously tested EALA peptide. To evaluate whether
this objective was realized, the 29-amino-acid peptide
was mixed with PI-loaded liposomes at a lipid to
peptide ratio of 10 000:1 and compared with EALA
at the same peptide ratio. As expected, neither pep-
tide promoted measurable content release at neutral
pH; however, as pH was lowered into the endosomal
range (pH 4^6), the newly designed peptide was sig-
ni¢cantly more e¡ective than EALA (Fig. 3). Since
these two peptides demonstrated indistinguishable
behavior at higher peptide concentration (data not
shown), it is conceivable that glutamic acid place-
ment is only critical when very small amounts of
peptide are present. However, since a liposome’s car-
rying capacity can often limit its usefulness, minimi-
zation of the volume consumed by the lytic peptide
constitutes a desirable objective.
3.4. The 29-amino-acid peptide is signi¢cantly more
active than the 15-amino-acid truncated version at
low pH, and less active at physiological pH
We also wished to evaluate whether a shorter ver-
sion of the same sequence might retain the desirable
properties of the 29-amino-acid peptide, thereby con-
suming even less of the liposome’s internal volume.
For this purpose, a 15-residue peptide was obtained
and compared with the above peptide of the same
sequence. Both the 29- and 15-amino-acid peptides
were found to destabilize liposomes with the desired
pH dependence at relatively high peptide concentra-
Fig. 1. (A) Diagram showing the e¡ect of hydrophilic residue
arrangement on potential pore formation. Amphipathic peptides
in helical conformation are represented by circles. The lipo-
somal bilayer and aqueous pore volume are shown in light gray
and dark gray, respectively. For peptides with hydrophilic
charged residues distributed along a wide angle on the helix
(top left), a large number of molecules will be needed to form
an aqueous pore in a lipid bilayer (top right). When charged
residues are con¢ned to a smaller angle (bottom left), hydro-
philic interactions should be satis¢ed by the formation of a
smaller pore at lower peptide concentration (bottom right).
(B) Comparison of partial sequence helical wheel diagrams of
EALA, and the novel 29- and 15-amino-acid peptides. EALA
(left) possesses glutamic acid residues distributed over a large
angle and interspersed with hydrophobic residues (similar to
GALA), whereas the 29- and 15-amino-acid peptides (middle
and right helical wheels, respectively) possess glutamic acid resi-
dues con¢ned within a smaller angle of the helix.
Fig. 2. Liposomal release of both propidium iodide (PI) and a
10 000 Mr dextran is complete after 10 min incubation with the
29-amino-acid peptide. Egg phosphatidylcholine liposomes en-
capsulating either PI (F) or 10 000 Mr Texas Red-labeled dex-
tran (a) were incubated with the 29-amino-acid peptide at a
100:1 lipid to peptide ratio. Leakage of either marker from
liposomes was assessed at varying time points following acidi¢-
cation to pH 4. PI leakage was measured following the addition
of calf thymus DNA to the incubated solution and dextran
leakage was determined using size-exclusion chromatography
and £uorescence detection, as described in Section 2.
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tions (Fig. 4a). However, as the lipid to peptide mo-
lar ratio increased from 50:1 to 100:1 and 500:1, the
15-residue peptide declined in potency whereas the
29-residue version did not (Fig. 4b,c). Although pep-
tides of intermediate length were not examined, these
data demonstrate that continual truncation of the 29-
residue peptide will eventually lead to loss of activity.
Importantly, a tendency to destabilize liposomes at
neutral pH constituted another disadvantage of the
shorter peptide. Thus, at pH 7.4, where very low
levels of leakage were observed with the longer pep-
tide, we consistently observed elevated (as high as
20%) PI release with the shorter peptide. Liposome
instability at physiological pH is obviously an unde-
sirable characteristic of any strategy designed to pro-
mote liposome unloading only following endocytosis.
3.5. Both novel peptides exhibit decreased activity in
cholesterol-containing membranes
Cholesterol can be incorporated into liposomes to
enhance stability and is often used when increased
membrane rigidity is needed to prolong circulation
time in vivo [4]. To characterize the above peptides’
behavior in cholesterol-containing membranes, both
long and short peptides were added to liposomes
containing 0, 20, or 40 mol% cholesterol and exam-
ined for their pH-induced membrane lytic properties.
As seen in Fig. 5, cholesterol was found to decrease
PI release induced by both the 29 and 15-amino-acid
peptides. However, whereas the activity of the short-
er peptide was severely compromised by increasing
cholesterol content, the activity of the longer peptide
was only mildly a¡ected. Thus, 40% cholesterol has
been commonly used in liposomes for in vivo appli-
cations, and at this cholesterol concentration and pH
4.5, the 29-residue peptide retained 75% of its initial
activity, whereas the shorter homolog displayed only
20% of its activity.
3.6. The 29-amino-acid peptide can form pores large
enough to release macromolecular dextrans from
liposomes
Because the 29-amino-acid peptide consistently
demonstrated superior properties to both EALA
and the 15-residue peptide, we decided to investigate
only the 29-amino-acid peptide further. In order to
explore the size of the membrane holes generated by
the 29-residue peptide, the peptide was incubated
with liposomes encapsulating 10 000 and 40 000 Mr
dextrans and dextran e¥ux was monitored. As seen
in Fig. 6, both dextrans were released from the lipo-
somes in a pH-dependent manner, however, the
smaller dextran escaped more e⁄ciently than the
larger one. Further, neither dextran was completely
discharged from liposomes during the 10-min incu-
bation period, even though PI could be entirely re-
leased under identical conditions. It should also be
noted that dextran release was only observed at very
high concentrations of peptide (lipid to peptide mo-
lar ratio of 50:1). The increased retention of larger
molecules by the perforated liposomes suggests that
peptide pore sizes are heterogeneous, with larger
pores forming only at higher peptide concentrations.
As a result of this, some liposomes may contain no
openings large enough to pass the macromolecular
dextrans.
3.7. Encapsulation of the 29-amino-acid peptide into
folate-targeted liposomes containing ara-C
increases their toxicity toward cultured
cancer cells V30-fold
In each of the above unloading experiments, pH
Fig. 3. The 29-amino acid peptide promotes more e⁄cient PI
release from liposomes compared to EALA. Either the 29-ami-
no acid peptide (F) or EALA (O) was incubated with egg
phosphatidylcholine liposomes encapsulating propidium iodide
(PI) for 10 min at a lipid to peptide ratio of 10 000:1 and a lip-
id concentration of 2.9 mM. Leakage of PI from liposomes was
determined 10 min later, as described in Section 2.
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Fig. 4. Both long and short peptides induce pH-dependent unloading of propidium iodide from liposomes. Either the 29-amino-acid
peptide (F) or the truncated 15-amino-acid peptide (a) was incubated with egg phosphatidylcholine liposomes encapsulating propidi-
um iodide (PI) for 10 min at various pH. Leakage of PI from the liposomes was assessed at various lipid to peptide ratios: 50:1 (A),
100:1 (B), and 500:1 (C) as described in Section 2. Lipid concentration was maintained at 2.9 mM.
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was arti¢cially changed to mimic the acidi¢cation
which occurs during receptor-mediated liposome en-
docytosis by a folate receptor-expressing cancer cell.
To test whether the 29-residue peptide might actually
function in this manner in a living cell, the peptide
was co-encapsulated with the anti-cancer drug, cyto-
sine arabinoside, in folate-targeted liposomes (con-
taining 0.5 mol% folate-PEG-PE), and the liposomes
were incubated with folate receptor-expressing hu-
man KB cells [26]. As seen in Fig. 7, the 29-amino-
acid peptide measurably enhances the toxicity of ara-
C to cancer cells. Thus, under conditions where fo-
late-targeted liposomes containing ara-C exhibit little
toxicity towards KB cells, co-encapsulation of the
peptide results in 30% growth inhibition. Further-
more, liposomes containing the 29-residue peptide,
but no ara-C, demonstrated negligible toxicity (data
not shown), indicating that cytotoxicity was not
caused by the peptide. The delivery of folate-targeted
liposomes containing peptide and ara-C was also ex-
amined using 2 mM free folic acid in the cell culture
medium as a competitive inhibitor of the folate re-
ceptor. As expected, the toxicity of these liposomes
was 6 5% of the non-competed sample (data not
shown). This result con¢rms that liposome uptake
and the subsequent cytotoxicity is mediated by the
folate receptor [27].
Fig. 7. The toxicity of liposomal ara-C to cultured KB cells is
enhanced by the 29-amino-acid peptide. Folate-targeted egg
phosphatidylcholine liposomes (containing 0.5 mol% folate-
PEG-PE) encapsulating ara-C only (b) or ara-C and 29-amino-
acid peptide (F) were incubated with KB cells for 4 h. Ara-C
concentration, reported on the x-axis, was determined by UV
absorbance of detergent-lysed liposomes in solution. Cytotoxic-
ity was determined 24 h later using a [3H]thymidine incorpora-
tion assay, as described in Section 2.
Fig. 6. The 29-amino-acid peptide induces pH-dependent un-
loading of encapsulated dextrans from liposomes. Egg phospha-
tidylcholine liposomes encapsulating 10 000 Mr (8) or 40 000
Mr (W) Texas Red-labeled dextrans were incubated for 10 min
with the 29-residue peptide at a 50:1 lipid to peptide ratio.
Dextran leakage was assessed following incubation at various
pH. Lipid concentration was maintained at 2.9 mM.
Fig. 5. Cholesterol reduces peptide-induced pH-dependent un-
loading of PI. Egg phosphatidylcholine liposomes containing 0,
20 or 40 mol% cholesterol were incubated with the 29 (solid
lines and symbols) or 15 (dotted lines and open symbols) -resi-
due peptide at pH 4.0 (squares), 4.5 (circles), or 5.0 (triangles).
Leakage of PI from the liposomes was assessed after 10 min in-
cubation, as described in Section 2. Lipid concentration was
maintained at 0.1 mM, and lipid to peptide ratio was 100:1.
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3.8. The 29-amino-acid peptide enhances
folate-targeted transfection of KB cells by
serum-stable DNA-DOTAP/cholesterol
complexes
The encouraging results with peptide-assisted drug
delivery led us to explore the utility of the 29-amino-
acid peptide in enhancing the potency of various
gene therapy formulations. For this purpose, DO-
TAP/cholesterol liposomes were complexed with dif-
ferent ratios of the peptide and a luciferase expres-
sion vector, and the complex was then examined for
transfection e⁄ciency following incubation with KB
cells in the absence (Fig. 8a) or presence (Fig. 8b) of
serum. Without serum or peptide present (Fig. 8a,
¢rst set of bars), no folate-targeted enhancement of
transfection was observed (please note that with oth-
er liposomal vector formulations folate targeting sig-
ni¢cantly enhances transfection even in the absence
of serum and peptide [11,28]). Thus, the cationic
charge on the cationic liposomal vector complexes
was apparently su⁄cient to dominate the binding
and release of plasmid into the KB cells. However,
in the case of folate-targeted liposomes, increasing
the amount of peptide enhanced transfection up to
an optimum peptide/DNA weight ratio of 1:1. With
non-targeted liposomes, addition of the peptide did
little to enhance the potency of the vectors. This
result may have arisen because the non-targeted lipo-
somal vectors could have entered the cytoplasm at an
earlier stage of the endocytic pathway, perhaps by a
pH-independent mechanism [29]. The result is also
interesting, because it implies that endosome escape
could constitute a critical variable governing the e⁄-
ciency of targeted liposomal vectors. Thus, while the
peptide cannot in£uence folate receptor binding or
receptor-mediated endocytosis, without peptide cat-
alysis of DNA escape from the endosomes, the fo-
late-targeted vector was largely ine¡ective in promot-
ing gene expression. It was also observed that at
higher peptide/DNA ratios (above 1:1), the transfec-
tions decreased with both the both the targeted and
non-targeted complexes, suggesting that high amount
of peptide may interfere with proper cationic lipid/
DNA complex formation.
In contrast to transfections in the absence of se-
rum, analogous studies in the presence of serum in-
dicated that without peptide present, a 100-fold re-
duction in non-targeted transfections but only a 10-
fold reduction in targeted transfections was observed
(Fig. 8b, ¢rst set of bars). Thus, while serum proteins
likely coated the cationic vector complexes and re-
duced the binding ability of the non-targeted com-
plexes, shielding of charge interactions in the tar-
geted complexes was probably compensated in part
by association of the folate targeting ligand with fo-
Fig. 8. The 29-amino-acid peptide enhances the folate-targeted
transfection e⁄ciency of DOTAP/cholesterol liposomes. Trans-
fections were performed without serum (A) or in the presence
of 10% fetal bovine serum (B). Transfection particles were pre-
pared by complexing 0.1 Wg pGL3 DNA mixed with peptide (at
the indicated peptide/DNA weight ratios), with cationic lipo-
somes consisting of 60% DOTAP and 40% cholesterol. Folate-
targeted cationic liposomes contained 0.5% folate-PEG-PE
(black bars) and non-targeted liposomes contained 0.5% PEG-
PE (gray bars). KB cells in 96-well plates were transfected as
described in Section 3, and assay results are expressed as RLUs
per mg of cell lysate protein.
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late receptors on the cancer cell surfaces. The above
data suggest that the V250 Aî polyethylene glycol
spacer between folic acid and the lipid is su⁄cient
to enable the ligand to extend through the serum
protein coat. However, serum protein shielding of
the cationic charges on these vectors may still hinder
their lipid mixing/fusion properties, resulting in the
observed decrease in activity with both targeted and
non-targeted complexes. Hence, the peptide was
found to enhance both folate-targeted transfection
and non-targeted transfection at an elevated serum
content. This would suggest that some serum-coated
complexes still enter cells non-speci¢cally, but that
they ¢nd themselves in low-pH endosomes where
the peptide can enhance their unloading. In addition,
increasing the amount of peptide did increase trans-
fection, and a slightly higher peptide/DNA weight
ratio of 1.4:1 permitted optimal transfection of these
serum coated complexes.
4. Discussion
Many pH-sensitive peptides have been utilized as
possible catalysts of liposome unloading at low pH
[20,21,30^34]. Because none of these peptides exhibit
the pH sensitivity and potency that would warrant
their evaluation in clinical trials, we undertook the
design of a peptide that would retain the pH sensi-
tivity of previously studied peptides, yet exhibit a
potency that would encourage its evaluation for clin-
ical use. Based on the characteristics presented in
Figs. 2^8, we suggest that the novel 29-residue pep-
tide advances our progress toward this objective.
Thus, the peptide (i) causes negligible liposome leak-
age at pHs s 6.5, (ii) undergoes its lytic transition in
the endosomal pH range, (iii) remains functional in
cholesterol-containing liposomes, (iv) induces rapid
leakage (t1=26 10 min) upon acidi¢cation, (v) pro-
motes release of both low and high Mr cargos, and
(vi) functions at lower concentrations than the pre-
viously characterized EALA peptide.
A fundamental di¡erence between the GALA-like
peptides and our 29-amino-acid peptide lies in the
distribution of glutamic acid residues around each
peptide’s helical wheel. In GALA and EALA, the
glutamic acids are interspersed with leucine and ala-
nine residues on the same face of the helix. In the
new 29-amino-acid peptide, however, all glutamic
acids are situated on the same surface of the K-helix
and are not interrupted by intervening hydrophobic
residues. Interestingly, although our data demon-
strate that the 29-residue peptide is only membrane
active at low pH, these sequence alterations a¡ord
88% helical conformation to the peptide even at neu-
tral pH, as determined by circular dichroism [35].
Because no EALA surface exposes solely hydro-
philic residues, a well-de¢ned geometry of self-assem-
bly in the membrane may not occur. In contrast, the
geometry of self assembly of the 29-amino-acid pep-
tide in a bilayer should be more limited, since it has
well de¢ned hydrophilic and hydrophobic surfaces. It
has been previously shown that 4^6 GALA peptide
monomers are necessary for its assembly within the
bilayer [36], whereas 8^12 monomers are needed for
the formation of a transbilayer pore [31]. This is in
accordance with our simple model for bilayer assem-
bly (Fig. 1A) which predicts that roughly 8 mono-
mers are necessary for pore formation with either
GALA or EALA peptides. Using the same model,
we hypothesized that a peptide with glutamic acid
residues arranged around a smaller arc of the helical
wheel (i.e., as in our novel peptide) would require
fewer monomers for pore formation. This di¡erence,
however, would be expected to emerge only at very
limiting peptide concentration, when su⁄cient pep-
tide is available to form a tetrameric but not an
octameric pore. Indeed, measurable distinctions be-
tween EALA and the 29-mer became evident at very
low peptide concentrations, where the new peptide
clearly outperformed EALA. While the di¡erence
in potency may be considered relatively minor, be-
cause very low peptide concentrations can maximize
the volume available for co-encapsulated therapeutic
molecules, this di¡erence could impact the usefulness
of the peptide in therapeutic applications.
We suggest the di¡erences in liposome permeabil-
ity promoted by EALA and the new peptide also
support the hypothesis that a peptide with glutamic
acid residues arranged on a smaller angle of the hel-
ical wheel will form smaller sized membrane pores,
perhaps consisting of only a few peptide monomers
per channel (Fig. 1A). Thus, the essentially quantita-
tive release of PI from the liposomes demonstrated
that an aqueous channel of at least 1.5 nm in diam-
eter must have formed in virtually all peptide-con-
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taining liposomes. In contrast, the limited e¥ux of
the V10 000 and V40 000 Mr dextrans suggests that
considerably fewer pores of large diameter were
formed in the same liposomes. Still, the fact that
the macromolecular solutes were able to escape the
liposomes at all would suggest that the 29-residue
peptide can form very large pores when su⁄cient
peptide is present. However, the observation that
neither dextran was quantitatively released from the
liposomes further suggests that a measurable popu-
lation of liposomes must exist with openings too
small to accommodate any macromolecules.
Results from the studies with dextran-loaded lipo-
somes also allowed us to better de¢ne the mechanism
of action of our peptide. We have assumed that the
activity of the 29-residue peptide was due to forma-
tion of pores in a bilayer. Indeed, using this peptide,
molecules of increasing size were released with de-
creasing e⁄ciency, suggesting a size ¢lter exists in
the e¥ux pathway. The presence of a permeability
barrier with a strong size dependence argues more
for a mechanism of pore formation than detergent-
like membrane lysis or destabilization [31].
The 15-residue truncated peptide was also found
to facilitate the pH-dependent unloading of PI from
liposomes, but only at signi¢cantly higher concentra-
tions than required by its longer counterpart.
Whether the 29-residue version is, in fact, already
at its optimal length is not certain, since no other
homologous peptides were tested. The 29-residue
peptide was originally designed to just barely span
the bilayer. Thus, it was felt that a signi¢cantly
shorter peptide would not extend to both aqueous
compartments and would consequently be energeti-
cally unable to reside within the bilayer, thereby ren-
dering it membrane inactive. This assumption was
obviously wrong, as indicated in Fig. 4. In fact,
Puyal and coworkers have shown that the weak
membrane destabilizing activity of their 14-amino-
acid fusogenic peptide could be enhanced 1000-fold
if the peptide was directly linked to the liposomes
[37]. We also noticed that higher local concentrations
of the peptide allowed for greater membrane lytic
activity. Conceivably, direct conjugation of the 15-
amino-acid peptide to a lipid head group could
also resurrect this peptide’s usefulness.
As noted above, membrane lytic peptides may ei-
ther be covalently attached to a lipid head group or
co-encapsulated with the drug inside the liposome.
For our applications, we have chosen the co-encap-
sulation strategy, since in addition to promoting lipo-
some unloading, the peptide may subsequently be-
come available to insert into the endosomal bilayer
and further enhance cytoplasmic delivery of the drug
[22]. This latter component of the peptide’s activity is
likely to further enhance the cytotoxicity of the folate
targeted liposomal ara-C preparation. Obviously,
further work is also needed to determine the opti-
mum lipid composition for use with the 29-residue
peptide for in vivo drug delivery applications. Clin-
ical or ‘stealth’ liposomes have a very rigid bilayer
containing solid-phase lipid and a high percentage of
cholesterol. While these liposomes may be more dif-
¢cult to permeabilize than the egg phosphatidylcho-
line liposomes tested in this study, inclusion of cho-
lesterol in the latter formulation caused only minor
reduction in peptide potency.
A major limitation of non-viral gene delivery has
historically been the poor release of DNA from en-
dosomal compartments. Previous workers have
documented the ability of pH-sensitive peptides to
enhance the transfection e⁄ciency of non-targeted
fusogenic liposomal vectors [38]. Only recently have
serum-stable complexes been used in conjunction
with amphipathic peptides to enhance transfection
[39^41], but none of these preparations were tumor
targeted. We have demonstrated the feasibility of
employing a co-entrapped lytic peptide to enhance
the speci¢c receptor-targeted transfection of cancer
cells. The fact that our formulation was also serum
stable o¡ers hope that the peptide might be applied
for in vivo use.
In summary, we have characterized a novel peptide
that was designed to self-associate into small pore-
forming oligomers within membrane bilayers upon
acidi¢cation to endosomal pHs. Our data reveal
that this peptide retains the optimal pH sensitivity
of GALA-like peptides, but maintains its potency
at lower concentrations. Since it has also demon-
strated improved utility in combination with serum
stable, folate-targeted, liposomal gene therapy vec-
tors, we suggest that further characterization and
optimization of the system with in vivo applications
is warranted.
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